ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California. Show more

11682 El Camino Real, San Diego, CA, 92130, United States

Biotechnology

Healthcare

Market Cap

558.9M

52 Wk Range

$4.91 - $13.15

Previous Close

$5.67

Open

$5.60

Volume

852,847

Day Range

$5.54 - $5.70

Enterprise Value

516.7M

Cash

143.8M

Avg Qtr Burn

-60.93M

Insider Ownership

16.18%

Institutional Own.

92.08%

Qtr Updated

06/30/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
neffy® (epinephrine nasal spray) Details Anaphylaxis, Allergic Reactions (type I)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
neffy® (epinephrine nasal spray) Details Acute flares in patients with chronic spontaneous urticaria	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SBT6050 (TLR8 Agonist) Details Cancer, Breast cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.